Regentis Biomaterials Ltd.
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $11.4M
- Price
- $1.63
- % Change (Daily % change from the live per-ticker quote feed.)
- -1.21%
- Volume
- 17.0K
About
Regentis Biomaterials Ltd. is a regenerative medicine firm dedicated to crafting innovative solutions for tissue repair, ultimately aiming to enhance patients' health and overall quality of life. The company's primary product in development is GelrinC, a novel, cell-free, ready-to-use hydrogel designed to be solidified into an implant within the knee. This implant serves to address painful knee injuries and mend articular cartilage damage. Regentis Biomaterials leverages its proprietary Gelrin platform, which employs biodegradable hydrogel implants, to develop orthopedic therapies that facilitate the regeneration of compromised or diseased tissues. The company was established in 2004 and operates from its headquarters in Herzliya, Israel.
Quick stats
Shares outstanding7.0M
Computed float5.1M
Float / shares72.7%
Cash runway (months)15.8
Key info
SectorHealthcare
IndustryMedical - Instruments & Supplies
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001912966
Websitehttps://www.regentis.co.il
AI Summary
AI-generated1/8
minorneutralother
IBN Announces Latest Episode of The BioMedWire Podcast Featuring Dr. Ehud Geller, CEO of Regentis Biomaterials Ltd.
IBN, a paid investor-communications firm, released a new BioMedWire Podcast episode featuring Dr. Ehud Geller, Executive Chairman and CEO of Regentis Biomaterials (NYSE American: RGNT).
Geller said lead product GelrinC, a cell-free hydrogel for knee cartilage injuries, is already approved for marketing in Europe and is in a U.S. pivotal trial intended to win FDA permission to market in the U.S., with enrollment targeted to finish around the end of 2026.
He sized the currently untreated U.S. market at roughly 470,000 cartilage knee repair cases annually and said Regentis is in discussions with distributors and strategic orthopedic companies in Europe following its IPO.
The release discloses that IBN will receive $30,000 per quarter from RGNT for 180 days of coverage; no new clinical or financial data was provided.
Red flags
- Paid promotional content: IBN discloses it will receive $30,000 per quarter from RGNT for 180 days of coverage
- No new clinical data or hard milestones; enrollment completion 'approximately end of the year' is a management target only
- Small-cap relying on paid IR/podcast syndication -- a pattern sometimes associated with retail-facing stock promotion